Trial · NCT03650400
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pharmacokinetics of Fevipiprant by Area Under the Curve From 0 to 24 Hours at Steady State (AUC0-24h,ss), After at Least Four Consecutive Days of Dosing | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | h*ng/mL | MEAN |
| PRIMARY | Pharmacokinetics of Fevipiprant by Maximum Plasma Concentration at Steady State (Cmax,ss), After at Least Four Consecutive Days of Dosing | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | ng/mL | MEAN |
| PRIMARY | Pharmacokinetics of Fevipiprant by Oral Clearance at Steady State (CL/F), After at Least Four Consecutive Days of Dosing | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | L/h | MEAN |
| SECONDARY | Pharmacokinetics of Fevipiprant by CL/F | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours. | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | L/h | MEAN |
| SECONDARY | Pharmacokinetics of Fevipiprant by Tmax,ss | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | h | MEAN |
| SECONDARY | Urinary Excretion of Fevipiprant | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours. | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | L/h | MEAN |
| SECONDARY | Pharmacokinetics of Fevipiprant by Cmin,ss | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | ng/mL | MEAN |
| SECONDARY | Pharmacokinetics of the Metabolite CCN362 by AUC0-24h,ss | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | h*ng/mL | MEAN |
| SECONDARY | Pharmacokinetics of the Metabolite CCN362 by Cmax,ss | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | ng/mL | MEAN |
| SECONDARY | Pharmacokinetics of the Metabolite CCN362 by Cmin,ss | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | ng/mL | MEAN |
| SECONDARY | Pharmacokinetics of the Metabolite CCN362 by Tmax,ss | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours) | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | h | MEAN |
| SECONDARY | Urinary Excretion of the Metabolite, CCN362 | End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours. | All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination. | L/h | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03650400/outcomes